Amber Tx in a $100m (£80m) in Series A led by NEA, joined by F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises and 8VC.

Biotech Health services Pharma

United Kingdom

United States

Investments

02 June 2024

Share:

Amber Therapeutics (company)

United Kingdom

Biotech Health services Pharma

Total investments received (USD): 100.8m

Round value (USD): 100.8m

Round investors: F-Prime Capital New Enterprise Associates Oxford Science Enterprises 8VC Intuitive Ventures Lightstone Ventures

Company: Amber Therapeutics

Industry: Biotech Health services Pharma

Related deals

Purespring Therapeutics raised £80M series B led by Sofinnova Partners, joined by British Patient Capital, Syncona, Gilde Healthcare and Forbion.

Biotech Health services

United Kingdom

Netherlands

France

Investments 02 October 2024

Vicebio raised $100M with TCG Crossover, venBio Partners, UniQuest, Medicxi, Goldman Sachs Alternatives and Avoro Ventures

Biotech Health services

United Kingdom

United States

South Korea

Investments 17 September 2024

F2G raised a $100m round co-led AMR Action Fund and ICG, joined by Novo, Advent Life, Sofinnova, Forbion, Blue Owl, Morningside, and Merifin Capital.

Biotech Health services Pharma

United Kingdom

United States

Netherlands

Denmark

France

Belgium

Investments 01 September 2024

Exscientia to merge operations with Recursion from the US in a $668m deal

Biotech Health services Pharma Software Services

United Kingdom

MA 02 August 2024

Myricx Bio raised $114m in Series A funding co-led by Abingworth and Novo Holdings, joined by insiders Brandon Capital and Sofinnova Partners.

Health services Pharma

United Kingdom

Australia

Denmark

France

Investments 01 July 2024